Subacute Sensorimotor Neuropathy Accompanied by Anti-ganglioside GM1 Antibody in a Patient with Lung Cancer

Nobuhiro Kanaji,Kodai Kume,Hitoshi Mizoguchi,Takuya Inoue,Naoki Watanabe,Noriko Nishiyama,Norimitsu Kadowaki,Tomoya Ishii
DOI: https://doi.org/10.2169/internalmedicine.0667-17
2018-11-15
Abstract:A 66-year-old man presented with subacute sensorimotor neuropathy in association with small cell lung cancer. Tests for the anti-ganglioside antibody GM1-IgM were positive. Chemotherapy and intravenous immunoglobulin treatment led to a slight improvement in neurological symptoms. Four additional cases of neuropathy accompanied by anti-ganglioside antibody and lung cancer have been reported. The most commonly reported pattern was subacute sensorimotor neuropathy. Patients died from cancer progression after 5 to 18 months. There is evidence that anti-ganglioside antibody inhibits tumor progression, prolonging the patient survival. However, severe neurological disturbance may offset the survival benefit of anti-ganglioside antibody in patients with paraneoplastic neurological syndrome.
What problem does this paper attempt to address?